ADVISORY/Landmark Trial Results Demonstrate That Carvedilol Saves Lives and Substantially Reduces the Risk of a Second Heart Attack in High Risk Patients.Business Editors & Health/Medical Writers ADVISORY...for Tuesday (March 20) NOTE TO EDITORS: Multimedia Assets Available With This Story Include Logos, Text News Releases --(BUSINESS WIRE) Groundbreaking clinical trial results have demonstrated that long-term treatment with the beta blocking agent blocking agent n. A drug that blocks transmission of nerve impulses at an autonomic receptor site, autonomic synapse, or neuromuscular junction. carvedilol following a heart attack can reduce the risk of patients having another heart attack by 41 percent and dying by 23 percent. These results are from the landmark CAPRICORN (CArvedilol Post InfaRction infarction, blockage of blood circulation to a localized area or organ of the body resulting in tissue death. Infarctions commonly occur in the spleen, kidney, lungs, brain, and heart. SurvIval COntRol in Left Ventricular DysfunctioN ventricular dysfunction, n an abnormality in contraction and wall motion within the ventricles. ) trial, which were presented March 20 at the 50th Annual Scientific Session of the American College of Cardiology The American College of Cardiology (ACC) is a nonprofit medical association established in 1949 to educate, research and influence health care public policy. The president for the 2006–2007 year is Steven E. Nissen. [1] The organization has 39 chapters in the U.S. (ACC See adaptive cruise control. ). You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?2384 This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion